Source comparison
BPC-157 Studied Lyme Disease Research: Comparison of Mechanisms
Cytokine Modulation Reduces TNF-α and IL-6 via NF-κB inhibition without global immunosuppression Broad COX-2 inhibition reduces prostaglandin synthesis. No effect on cytokine gene transcription BPC-157 targets the inflammatory transcription pathway; NSAIDs add
This comparison does not assign a generated winner or score.
- Cytokine Modulation
- Reduces TNF-α and IL-6 via NF-κB inhibition without global immunosuppression
- Broad COX-2 inhibition reduces prostaglandin synthesis. No effect on cytokine gene transcription
- BPC-157 targets the inflammatory transcription pathway; NSAIDs address downstream mediators only
- Vascular Repair
- Upregulates eNOS and VEGF signalling, promoting endothelial healing and angiogenesis
- No angiogenic activity; prolonged use can impair wound healing
- Lyme-associated vascular damage requires repair, not just inflammation suppression
- Tissue Healing
- Enhances fibroblast proliferation and collagen synthesis in damaged joints and nervous tissue
- No tissue repair mechanism; symptomatic relief only
- PTLDS involves structural damage (synovial inflammation, demyelination) that requires regenerative pathways
- Immune Selectivity
- Preserves adaptive immune function while reducing pro-inflammatory cytokine storms
- Non-selective; can impair both innate and adaptive responses with chronic use
- Critical distinction: immune modulation in infectious disease contexts must avoid global suppression
- Evidence Base
- Preclinical only. No human RCTs in Lyme disease; extrapolated from sepsis and IBD models
- FDA-approved for inflammatory conditions; extensive human safety data
- NSAIDs have proven short-term efficacy for symptom management but no evidence of disease-modifying effects in PTLDS